Approved HCV Drugs
Approved HCV Drugs
EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
Adding the approved HCV protease inhibitor telaprevir (Incivek or Incivo) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Keith Alcorn
Currently available triple therapies for hepatitis C using HCV protease inhibitors carry a high risk of serious side effects for patients in the most urgent need of treatment, and these individuals have only a moderate chance of being cured, according to findings from studies of telaprevir and boceprevir treatment in cirrhotic patients at liver centers in France and Austria reported last week at the 48th International Liver Congress in Amsterdam. In the Austrian study almost 1 in 10 cirrhotic patients were hospitalized with sepsis during triple therapy.
CROI 2013: Telaprevir Triple Therapy Improves HCV Response for Black Null Responders
- Details
- Category: HCV Treatment
- Published on Wednesday, 10 April 2013 00:00
- Written by Liz Highleyman
Adding the HCV protease inhibitor telaprevir (Incivek) to pegylated interferon and ribavirin increased end-of-treatment response rates for difficult-to-treat patients including African-Americans who previously did not respond to interferon, according to study results presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013)in Atlanta.
EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- Details
- Category: HCV Treatment
- Published on Sunday, 28 April 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek), according to a report presented at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
Updated Boceprevir (Victrelis) Label Adds Data on Prior Null Responders
- Details
- Category: HCV Treatment
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) announced this week that the product label information for the hepatitis C virus (HCV) protease inhibitor boceprevir (brand name Victrelis) has been updated to include data on treatment of prior null responders.
More Articles...
- Boceprevir and Telaprevir Improve Hepatitis C Treatment, Literature Reviews Find
- AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis
- Hepatitis C Treatment Reduces HIV Progression and Death in HIV/HCV Coinfected
- EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes
Web Design and Development by